Article
Oncology
Praveen Vikas, Hans Messersmith, Carolyn Compton, Lynette Sholl, Russell R. Broaddus, Anjee Davis, Maria Estevez-Diz, Rohan Garje, Panagiotis A. Konstantinopoulos, Aliza Leiser, Anne M. Mills, Barbara Norquist, Michael J. Overman, Davendra Sohal, Richard C. Turkington, Tyler Johnson
Summary: The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) for patients considered for immune checkpoint inhibitor therapy. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. ASCO endorses the recommendations from the CAP guideline.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Shuangshuang Zhao, Lingli Chen, Yuqin Zang, Wenlu Liu, Shiqi Liu, Fei Teng, Fengxia Xue, Yingmei Wang
Summary: Lynch syndrome (LS) is caused by germline pathogenic variants in mismatch repair (MMR) genes, leading to LS-associated endometrial cancer (LS-EC) which has specific clinicopathologic features. Screening, diagnosis, surveillance, prevention and treatment for LS-EC have significantly advanced, with recommendations for universal LS screening among EC patients.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Immunology
Jiao-Ting Chen, Yu-Wen Zhou, Ting-Rui Han, Jun-Lun Wei, Meng Qiu
Summary: Surgical resection is essential for achieving good prognoses in colorectal cancer (CRC), but some patients fail to meet surgical indications or achieve pathological complete response after surgery. Perioperative therapy can effectively decrease tumor staging and reduce recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have shown satisfactory efficacy and safety in patients with high microsatellite instability/deficient mismatch repair (MSI-H/dMMR), while the therapeutic effect is minimal in patients with mismatch repair-proficient or microsatellite stable (pMMR/MSS). Additional predictors are needed to screen patients with potential clinical benefits. Different combinations of immunotherapy in perioperative clinical trials for CRC have been comprehensively summarized in this review, focusing on efficacy and safety, and pointing out future directions.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Marta Mendiola, Victoria Heredia-Soto, Ignacio Ruz-Caracuel, Amparo Baillo, Jorge Luis Ramon-Patino, Francisco Javier Escudero, Maria Miguel, Alberto Pelaez-Garcia, Alicia Hernandez, Jaime Feliu, David Hardisson, Andres Redondo
Summary: This study aimed to establish and compare different approaches for assessing the MMR status in endometrial carcinomas. A total of 126 early-stage EC samples were analyzed using immunohistochemistry, PCR-based MSI, methylation-specific multiplex ligation-dependent probe amplification, and targeted next-generation sequencing. The study found that approximately 53.2% of the samples were MMR deficient, while 46.8% were MMR proficient. Additionally, 44.3% of the samples showed genetic or epigenetic alterations, with MLH1 promoter methylation being the most common event.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
C. Gomez-Raposo, M. Merino Salvador, C. Aguayo Zamora, B. Garcia de Santiago, E. Casado Saenz
Summary: The incidence of endometrial cancer is rising globally. Prognosis and treatment options vary for early-stage and recurrent/metastatic patients, where immune check-point inhibitors are showing promise, particularly for those with specific genetic markers.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Yipeng Song, Jian Huang, Dandan Liang, Ying Hu, Beibei Mao, Qiujing Li, Huaibo Sun, Ying Yang, Jiao Zhang, Henghui Zhang, Huan Chen, Hao Liu, Shukun Zhang
Summary: Research suggests that mutations in DDR genes are common in CRC patients and are associated with improved overall survival. DDR mutations are also linked to higher tumor mutational burden, increased immune cell infiltration, and immune checkpoint molecule expression.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Mark A. Glaire, Neil A. J. Ryan, Marieke E. Ijsselsteijn, Katarzyna Kedzierska, Sofia Obolenski, Reem Ali, Emma J. Crosbie, Tjalling Bosse, Noel F. C. C. de Miranda, David N. Church
Summary: Defective DNA mismatch repair (dMMR) leads to elevated tumour mutational burden (TMB) and microsatellite instability (MSI), which is associated with better prognosis in colorectal cancer (CRC) but not in endometrial cancer (EC). The study reveals that CRC has a more robust immune response to dMMR/MSI compared to EC, as evidenced by increased density of tumor-infiltrating T cells.
JOURNAL OF PATHOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Sandrine Rousset-Rouviere, Philippe Rochigneux, Anne-Sophie Chretien, Stephane Fattori, Laurent Gorvel, Magali Provansal, Eric Lambaudie, Daniel Olive, Renaud Sabatier
Summary: Endometrial cancer can be easily cured at early stage, but advanced and metastatic cases are common. Recent studies have shown the impact of PD-1 and PD-L1 inhibitors on chemo-resistant EC, with promising results for both MSI-high and MMRp cases. Combinations with other targeted therapies and ICI-chemotherapy triplets are being evaluated for future development.
Article
Oncology
Cara Mathews, Domenica Lorusso, Robert L. Coleman, Susan Boklage, Jamie Garside
Summary: This study found that dostarlimab has favorable efficacy and safety profiles for patients with dMMR/MSI-H advanced/recurrent endometrial cancer through an indirect treatment comparison.
Review
Oncology
Chang Woo Kim, Hong Jae Chon, Chan Kim
Summary: In colorectal cancer, microsatellite stable (MSS) patients display resistance to immunotherapy through multiple mechanisms including low tumor immunogenicity, activation of the WNT/beta-catenin pathway, presence of immunosuppressive cells, and liver metastasis. Combination therapies using various agents are being explored to overcome these resistance mechanisms.
Review
Oncology
Khalil Choucair, Maluki Radford, Ajay Bansal, Robin Park, Anwaar Saeed
Summary: Microsatellite instability-high/deficient mismatch repair colorectal cancer (MSI-H/dMMR CRC) is a molecular subtype characterized by high-frequency mutations within DNA mismatch repair genes, leading to sensitivity to immune checkpoint inhibitors (ICIs). This review focuses on major randomized clinical trials, molecular background, and resistance mechanisms, as well as ongoing investigations of immunotherapeutic strategies to enhance response to ICIs.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Article
Oncology
Francesca Corti, Sara Lonardi, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Carmen Belli, Beatrice Borelli, Marta Brambilla, Alessandra A. Prete, Virginia Quara, Maria Antista, Matteo Fassan, Federica Morano, Andrea Spallanzani, Margherita Ambrosini, Giuseppe Curigliano, Filippo de Braud, Vittorina Zagonel, Giovanni Fuca, Filippo Pietrantonio
Summary: The Pan-Immune-Inflammation Value (PIV) proved to be a strong predictor of outcomes in MSI-high mCRC patients receiving ICIs, and both high baseline PIV and early PIV increase were associated with poorer overall survival and progression-free survival. Early PIV increase was identified as an independent predictor of clinical benefit.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Camille Evrard, Jerome Alexandre
Summary: Endometrial cancers are highly affected by microsatellite instability, showing sensitivity to immunotherapy and requiring molecular biology for better understanding. The phenotype is poorly understood in ovarian cancer but does exist. Examination of literature reveals the importance of deficient mismatch repair/microsatellite instability in gynecological cancers and the potential therapeutic and prognostic implications.
Article
Immunology
Weihuo Pan, Jianguo Zhao, Songou Zhang, Xiaozhen Chen, Wenqing Liang, Qingping Li
Summary: Immunotherapy has shown promising outcomes in the treatment of CRC, particularly in dMMR-MSI-H patients, but challenges and hurdles still exist. Further research on novel biomarkers and molecular signatures is needed to improve the effectiveness of immunotherapy in CRC treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Ying Yang, Wen-Jian Meng, Zi-Qiang Wang
Summary: Colorectal cancer (CRC) is a highly incident and lethal malignant tumor. Current treatment approaches, including surgery, chemotherapy, radiotherapy, and molecular targeted therapy, have improved overall survival. However, immune checkpoint inhibitors (ICIs) therapy has shown significant efficacy in high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) advanced CRC, but not in microsatellite stable (MSS) advanced CRC patients.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2023)
Article
Oncology
Naomi Iwasa-Inoue, Hiroyuki Nomura, Fumio Kataoka, Tatsuyuki Chiyoda, Tomoko Yoshihama, Yoshiko Nanki, Kensuke Sakai, Yusuke Kobayashi, Wataru Yamagami, Tohru Morisada, Akira Hirasawa, Daisuke Aoki
Summary: The study investigated the clinical benefit of dose-dense paclitaxel plus carboplatin with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer. The results showed that neoadjuvant dose-dense TC-bevacizumab therapy was well tolerated and achieved a satisfactory rate of complete resection by IDS, indicating high efficacy and relative safety of NAC.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Geriatrics & Gerontology
Keiko Watanabe, Miho Iida, Sei Harada, Suzuka Kato, Kazuyo Kuwabara, Ayako Kurihara, Ayano Takeuchi, Daisuke Sugiyama, Tomonori Okamura, Asako Suzuki, Kaori Amano, Akiyoshi Hirayama, Masahiro Sugimoto, Tomoyoshi Soga, Masaru Tomita, Yusuke Kobayashi, Kouji Banno, Daisuke Aoki, Toru Takebayashi
Summary: Multiple charged metabolites were associated with women's menopausal status, showing a gradual increase as women shifted from pre-, to peri-, to postmenopause. These findings might reflect the early changes behind the increased risk of dyslipidemia, diabetes, cardiovascular disease, and osteoporosis in later life.
Article
Chemistry, Medicinal
Yusuke Kobayashi, Takashi Takeda, Haruko Kunitomi, Fumiko Chiwaki, Masayuki Komatsu, Shimpei Nagai, Yuya Nogami, Kosuke Tsuji, Kenta Masuda, Hideaki Ogiwara, Hiroki Sasaki, Kouji Banno, Daisuke Aoki
Summary: Statins show promise in ovarian cancer treatment, with the potential for personalized treatment based on biomarker identification. VDAC1 and LDLRAP1 are found to be correlated with response to statins. Further clinical trials are warranted to repurpose statins for ovarian cancer treatment based on biomarker expression.
Article
Obstetrics & Gynecology
Yusuke Matoba, Wataru Yamagami, Tatsuyuki Chiyoda, Yusuke Kobayashi, Eiichiro Tominaga, Kouji Banno, Daisuke Aoki
Summary: This study analyzed the risk factors for ovarian metastasis in endometrial cancer patients and identified the appropriate patient population for ovarian preservation surgery.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Masayuki Komatsu, Kanako Nakamura, Takashi Takeda, Fumiko Chiwaki, Kouji Banno, Daisuke Aoki, Fumitaka Takeshita, Hiroki Sasaki
Summary: This study proposes a new concept of inducing addiction to oncogenic signaling through specific blockade of target molecules. In experiments with cervical squamous cell carcinoma cells, dual blockade of Aurora A/B led to rapid addiction to EGFR-Erk signaling, and the synergistic inhibition of this signaling enhanced anti-cancer activities in vitro, in vivo, and in a patient-derived organoid model.
Article
Oncology
Tomoko Yoshihama, Yuka Kuroda, Tatsuyuki Chiyoda, Mio Takahashi, Takuma Yoshimura, Keiko Saotome, Yoshiko Nanki, Kensuke Sakai, Yusuke Kobayashi, Wataru Yamagami, Daisuke Aoki
Summary: This study retrospectively evaluated the efficacy and safety of olaparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer. The results showed that olaparib maintenance therapy is safe and no less effective than previous studies in the Japanese population.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Reina Ooka, Yoshiko Nanki, Wataru Yamagami, Miho Kawaida, Shimpei Nagai, Takuro Hirano, Kensuke Sakai, Takeshi Makabe, Tatsuyuki Chiyoda, Yusuke Kobayashi, Fumio Kataoka, Daisuke Aoki
Summary: This study compares the accuracy of preoperative endometrial biopsy and MRI with intraoperative frozen section in diagnosing endometrial cancer. The results show that there is no significant difference between preoperative and intraoperative diagnoses for histologic type and grade, but intraoperative diagnosis is more accurate in determining myometrial invasion.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2023)
Editorial Material
Oncology
Yusuke Kobayashi, Hiroaki Komatsu, Masanori Isobe, Jyoti Meena, Chia-Sui Weng, Se Ik Kim, Jeslyn J. L. Wong, Shuk Tak Kwok, Jie Yang, Panida Mathaveechotikul, Kanddy Loo Chin Yee, Jae-Weon Kim, Kimio Ushijima
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Shoko Kitazawa, Tatsuyuki Chiyoda, Kohei Nakamura, Kensuke Sakai, Tomoko Yoshihama, Hiroshi Nishio, Yusuke Kobayashi, Takashi Iwata, Kouji Banno, Wataru Yamagami, Hiroshi Nishihara, Daisuke Aoki
Summary: This study aimed to determine the potential availability and utility of gene panel testing clinically in gynecologic oncology. The study found that many patients had druggable gene alterations, but only 10.8% of them received the recommended treatment. TMB-H was mainly observed in cervical/endometrial cancer, suggesting its potential as a therapeutic biomarker of immune checkpoint inhibitors.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yusuke Kobayashi, Kenta Masuda, Akira Hiraswa, Kazuhiro Takehara, Hitoshi Tsuda, Yoh Watanabe, Katsutoshi Oda, Satoru Nagase, Masaki Mandai, Aikou Okamoto, Nobuo Yaegashi, Mikio Mikami, Takayuki Enomoto, Daisuke Aoki, Hidetaka Katabuchi
Summary: A survey of gynecologic oncologists in Japan revealed that they are facing psychological burdens in managing HBOC practices. Strengthening human resources, improving educational opportunities, and expanding insurance coverage are key factors to promote HBOC management.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Takayuki Takahashi, Hikaru Matsuoka, Rieko Sakurai, Jun Akatsuka, Yusuke Kobayashi, Masaru Nakamura, Takashi Iwata, Kouji Banno, Motomichi Matsuzaki, Jun Takayama, Daisuke Aoki, Yoichiro Yamamoto, Gen Tamiya
Summary: This study developed an artificial intelligence (AI) algorithm that can accurately detect high-grade lesions associated with prognosis using colposcopic images. The results provide insight into the additional utility of colposcopy for managing patients with CIN2.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Tomoko Akahane, Kenta Masuda, Akira Hirasawa, Yusuke Kobayashi, Arisa Ueki, Miho Kawaida, Kumiko Misu, Kohei Nakamura, Shimpei Nagai, Tatsuyuki Chiyoda, Wataru Yamagami, Shigenori Hayashi, Fumio Kataoka, Kouji Banno, Kokichi Sugano, Hajime Okita, Kenjiro Kosaki, Hiroshi Nishihara, Daisuke Aoki
Summary: This study revealed a higher detection rate of TP53 pathogenic variants in patients undergoing RRSO with BRCA1/2 pathogenic variants compared to the control group, while no difference was observed in the frequency of p53 signatures between the two groups. TP53 sequencing analysis in several patients showed two different types of p53 signatures.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Takashi Takeda, Kosuke Tsuji, Yusuke Kobayashi, Kouji Banno, Daisuke Aoki
Summary: This study retrospectively analyzed gynecologic malignant tumor patients who underwent microsatellite instability testing, finding MSI-H most commonly detected in endometrial cancer but less frequently as a companion diagnosis for pembrolizumab. Among 6 Lynch syndrome patients, 37.5% showed MSI-H.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)